Coloplast (BRSE:020259063) - Aandelenkoers, Nieuws & Analyse

020259063 Overzicht aandelen

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Meer informatie

020259063 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	3/6
Dividenden	3/6

Beloningen

De koers-winstverhouding ( 39.4 x) ligt onder het gemiddelde van de Medical Equipment -industrie ( 36.7 x)

De winst zal naar verwachting met 10.15% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Het dividend van 2.29% wordt niet goed gedekt door de winst of de vrije kasstromen

Heeft een hoog schuldenniveau

Coloplast A/S Concurrenten

Alcon

SWX:ALC

CHF 37.8b

Ypsomed Holding

SWX:YPSN

CHF 4.9b

Sonova Holding

SWX:SOON

CHF 18.9b

Straumann Holding

SWX:STMN

CHF 17.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Coloplast
Historische aandelenkoersen
Huidige aandelenkoers	DKK 109.67
52 Week Hoogtepunt	DKK 143.26
52 Week Laag	DKK 102.98
Bèta	0.24
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	-4.64%
33 jaar verandering	-0.17%
5 jaar verandering	41.23%
Verandering sinds IPO	33.34%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	020259063	CH Medical Equipment	CH Markt
7D	0%	-5.2%	-2.2%
1Y	-4.6%	13.8%	6.2%

Rendement versus industrie: 020259063 presteerde slechter dan de Swiss Medical Equipment -sector, die het afgelopen jaar een rendement van 13.8 % opleverde.

Rendement versus markt: 020259063 presteerde slechter dan Swiss Market, dat het afgelopen jaar een rendement van 6.2 % opleverde.

Prijsvolatiliteit

Is 020259063's price volatile compared to industry and market?
020259063 volatility
020259063 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	3.9%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	1.6%

Stabiele aandelenkoers: 020259063 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 020259063 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1954	14,572	Kristian Villumsen	www.coloplast.com

Coloplast A/S Samenvatting

Hoe verhouden de winst en inkomsten van Coloplast zich tot de beurswaarde?
020259063 fundamentele statistieken
Marktkapitalisatie	CHF 24.53b
Inkomsten(TTM)	CHF 622.66m
Inkomsten(TTM)	CHF 2.99b

39.4x

Koers/Winstverhouding

8.2x

P/S-verhouding

Is 020259063 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
020259063 resultatenrekening (TTM)
Inkomsten	DKK 22.58b
Kosten van inkomsten	DKK 7.05b
Brutowinst	DKK 15.53b
Overige uitgaven	DKK 10.82b
Inkomsten	DKK 4.71b

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

Feb 03, 2023

Winst per aandeel (EPS)	22.17
Brutomarge	68.78%
Nettowinstmarge	20.84%
Schuld/Eigen Vermogen Verhouding	217.1%

Hoe presteerde 020259063 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.3%

Huidig dividendrendement

90%

Uitbetalingsratio

020259063 Overzicht aandelen

Beloningen

Risicoanalyse

Coloplast A/S Concurrenten

SWX:ALC

CHF 37.8b

SWX:YPSN

CHF 4.9b

SWX:SOON

CHF 18.9b

SWX:STMN

CHF 17.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Less than half of directors are independent

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

First quarter 2021 earnings released

Revenue beats expectations

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Coloplast A/S Samenvatting

39.4x

8.2x

Inkomsten en omzet

Dividenden

2.3%

90%